Dual checkpoint inhibition in gallbladder cancer: Bridging new hope with the need for biomarkers-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Dual checkpoint inhibition in gallbladder cancer: Bridging new hope with the need for biomarkers

Published:2024-06-14 Issue:17 Volume:130 Page:2904-2906
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Saj Fen¹^ORCID,Wu Y. Linda²^ORCID,Pant Shubham³^ORCID,Goyal Lipika⁴^ORCID

Affiliation:

1. Department of Medical Oncology Balco Medical Center Raipur Chhattisgarh India

2. Division of Hematology and Oncology Herbert Irving Comprehensive Cancer Center Columbia University Irving Medical Center New York NY USA

3. Department of Gastrointestinal Medical Oncology The University of Texas MD Anderson Cancer Center Houston TX USA

4. Division of Oncology Department of Medicine Stanford School of Medicine Palo Alto CA USA

Abstract

Dual checkpoint blockade with nivolumab plus ipilimumab in patients with advanced, refractory gallbladder cancer showed activity in select patients in cohort 48 of the SWOG 1609 DART trial. Optimizing patient selection for this regimen will require validating predictive biomarkers of response and understanding the role of the regimen after chemoimmunotherapy in the frontline.

Publisher

Wiley

Reference19 articles.

1. Gallbladder cancer epidemiology, pathogenesis and molecular genetics: Recent update

2. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer

3. Precision Medicine and Immunotherapy Have Arrived for Cholangiocarcinoma: An Overview of Recent Approvals and Ongoing Clinical Trials

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP